Background/Aims: Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem. Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with refractory hepatic hydrothorax. Methods: Eleven consecutive patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical records and radiologic imagings of these patients were thoroughly reviewed. Results: The median number of chemical pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%), 5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks). Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%), azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall survival was significantly longer in the success group than in the non-success group. Conclusions: Although chemical pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine application of this procedure for such patients. (Korean J Hepatol 2011;17:292-298)
INTRODUCTION
Hepatic hydrothorax is defined as a significant pleural effusion, usually greater than 500 mL, in a patient with liver cirrhosis but no primary cardiac or pulmonary diseases. 1, 2 In patients with hepatic hydrothorax, even a modest volume of pleural fluid can cause respiratory symptoms, in contrast to ascites, where a large volume can be well tolerated.
Hepatic hydrothorax is a relatively uncommon complication of end-stage liver with an estimated prevalence of 5-10% among cirrhotic patients. [1] [2] [3] [4] In spite of the numerous case reports describing clinical features and treatments for hepatic hydrothorax the current knowledge of this complication of cirrhosis is limited. Unfortunately the pathogenesis and therapy of hepatic hydrothorax have not been appropriately studied, therefore, proper guidelines on therapy based on good evidence have been difficult to establish.
The aim of current study is to examine the treatment outcomes of the 11 patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS). 
PATIENTS AND METHODS

Patients
Statistical methods
Mann-Whitney U-test for continuous variables and Fisher's exact test for categorical variables were performed. The comparison of the cumulative survival rate between success and non-success group was performed using a log-rank test
with Kaplan-Meier analysis. Data were analyzed using 
RESULTS
A total of 11 patients with refractory hepatic hydrothorax were included. Median (range) age of the patients was 63
(38-84) years and 6 (54.5%) patients were male. The etiologies of liver cirrhosis were HBV (n=4, 36.2%), HCV (n=4, 36.4%), alcoholic (n=1, 9.1%) and cryptogenic (n=2, Conventional treatment modalities for hepatic hydrothorax such as sodium restriction and diuretics, and intermittent thoracentesis cannot achieve the goals of treatment in many patients. Increasing the doses of diuretics to achieve the negative sodium balance may increase in the serum creatinine level, which indicates a decrease in the glomerular filtration rate. 9 Moreover, increasing the doses of diuretics may precipitate hepatic encephalopathy. Although, thoracentesis for hepatic hydrothorax in clinical practice is both useful and safe, thoracentesis dependence may be associated with deteriorating clinical status and impaired quality of life.
Actually, when thoracentesis is required every 2-3 weeks, alternative strategies were needed to be considered. There are a few reports of successful primary repair of diaphragmatic defects. 8, 14 Evaluation for defects in the diaphragm formerly required a thoracotomy, which carries substantial risks. Recently, VATS was used to identify diaphragmatic defects in patients with refractory hepatic hydrothorax, and biologic glue or sutures were used to close the defects. 15 However, VATS also required a general anesthesia, which carries substantial risks for the patients with advanced liver cirrhosis. Additionally, in contrast to the series by Mouroux et al, 15 we did not identify any visible diaphragmatic defects in two patients who underwent chemical pelurodesis combined with VATS.
In a real clinical situation, where advanced liver cirrhosis patients with refractory hepatic hydrothorax who need symptomatic relief and the control of pulmonary complications are in the care of a physician who has a few available treatment modalities, chemical pleurodesis by tube thoracostomy may be a considerable treatment option for these intractable patients.
In the current study, success of treatment was identified as a significant prognostic indicator for patients with advanced liver cirrhosis and refractory hepatic hydrothorax. Previous study by Ferrante et al 8 also adopted the concept of success of treatment defined as control of symptomatic hydrothorax in the first 30 days after the VATS with talc pleurodesis.
However, they did not figure out any prognostic significance of this concept "success of treatment". However, in the current study, the patient who achieved the success of treatment showed significantly better outcomes than the patients who did not achieve the success of treatment.
The current study has limitations to consider. First, the number of enrolled patients with refractory hepatic hydrothorax is too small to draw any statistical significance.
Due to the rare frequency of hepatic hydrothorax, previously reported case series [6] [7] [8] 
